Response to salbutamol in patients with mild asthma treated with nadolol

Hanania, N.A.; Mannava, B.; Franklin, A. E.; Lipworth, Brian J.; Williamson, Peter; Garner, William J.; Dickey, Burton F.; Bond, Richard A.

doi:10.1183/09031936.00003210

Cited by 37 publications

(40 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk-benefit ratio of β-blocker maintenance therapy in asthmatics has a limited evidence base. This is further complicated by potential beneficial effects on airway inflammation and hyper-responsiveness in some patients with asthma (27)(28)(29) .…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Advances in the Diagnosis and Management of Asthma in Older Adults

Al‐Alawi

Hassan

Chotirmall

2014

The American Journal of Medicine

View full text Add to dashboard Cite

Global estimates on ageing predict an increased burden of asthma in the older population. Consequently, its recognition, diagnosis and management in clinical practice require optimization. This review aims to provide an update for clinicians highlighting advances in the understanding of the ageing process and immunosenescence together with their applicability to asthma from a diagnostic and therapeutic perspective. Ageing impacts airway responses, immune function and influences efficacy of emerging phenotype-specific therapies when applied to the elderly patient. Differentiating eosinophilic and neutrophilic disease accounts for atopic illness and distinguishes long-standing from late-onset asthma. Therapeutic challenges in drug delivery, treatment adherence and side effect profiles persist in the older patient while novel recording devices developed to aid detection of an adequate inhalation evaluates treatment effectiveness and compliance more accurately than previously attainable. Anti-cytokine therapies improve control of brittle asthma while bronchial thermoplasty is an option in refractory cases. Multi-dimensional intervention strategies prove best in the management of asthma in the older adult which remains a condition that is not rare but rarely diagnosed in this patient population.

show abstract

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Advances in the Diagnosis and Management of Asthma in Older Adults

Al‐Alawi

Hassan

Chotirmall

2014

The American Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…Nadolol is recommended for the treatment of hypertension, coronary disease and arrhythmia, moreover, according to recent studies it is also effective in the treatment of migraine and it can be safely applied against the above conditions even in the patients suffering from chronic mild asthma (Baker et al 2011;Lopez-Sendon et al 2004;Hanania et al 2010). …”

Section: Introductionmentioning

confidence: 99%

Radiodegradation of nadolol in the solid state and identification of its radiolysis products by UHPLC–MS method

et al. 2017

View full text Add to dashboard Cite

Nadolol ((2R*,3S*)-5-{[(2R*)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4 tetrahydronaphthalene-2,3-diol) in substantia was exposed to ionizing radiation generated by a beam of high-energy electrons in an accelerator, in the standard sterilisation dose of 25 kGy and in higher doses of 50 -400 kGy. The irradiated and non-irradiated (control) samples were analysed by the infrared spectrophotometry, electron paramagnetic resonance, differential scanning calorimetry (DSC) and ultrahigh performance liquid chromatography coupled with mass spectrometry (UHPLC-MS). The irradiated samples were found to contain free radicals in concentrations much higher than that observed for the other irradiated b-blockers. On the basis of UHPLC-MS results, it was possible to establish structures of 11 compounds of the impurities and/ or products of nadolol decomposition. The main product of radiodegradation was concluded to be formed as a result of abstraction of the hydroxyl group and aromatization of the tetrahydronaphthalene ring. The results of DSC measurements confirmed the presence of radiolysis products in the irradiated samples of nadolol. A shift of the endothermic peak corresponding to melting towards lower temperatures (by 4.4°C at the dose of 400 kGy) was directly proportional to the doses of radiation used, which permits concluding that this method is sensitive and suitable for evaluation of radiodegradation of nadolol in solid phase.

show abstract

“…In vivo studies have reported that barrestin-2 null mice have shown an attenuated asthma phenotype, and we have recently shown that administration of b 2 AR ligands capable of activating ERK1/2 in vitro (10, 12) restore the asthma-like phenotype in PNMT-KO mice, and do not attenuate the asthma-like phenotype in WT mice (16). There are even small clinical studies in subjects with asthma showing administration of nadolol, a ligand that inhibits b 2 AR-mediated activation of the ERK1/2 pathway (12), causes a dose-dependent reduction in AHR (reflected as an increase in the provocative concentration of methacholine causing a 20% drop in FEV 1 ) in subjects with mild asthma (41,42). Conversely, administration of propranolol, a ligand that activates the ERK1/2 pathway via the b 2 AR (12), had no effect in a different subset of subjects with asthma concurrently using inhaled corticosteroids (43).…”

Section: Discussionmentioning

confidence: 99%

Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β₂-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase–Knockout Mice

Forkuo

Kim

Thanawala

et al. 2016

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

Mice lacking the endogenous b 2 -adrenoceptor (b 2 AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of b 2 AR agonists to PNMT-KO mice restores the phenotype. Based on these and other studies showing differential effects of various b 2 AR ligands on the asthma phenotype, we have speculated that the permissive effect of endogenous epinephrine and exogenous b 2 AR agonists on allergic lung inflammation can be explained by qualitative b 2 AR signaling. The b 2 AR can signal through at least two pathways: the canonical Gas-cAMP pathway and a b-arrestin-dependent pathway. Previous studies suggest that b-arrestin-2 is required for allergic lung inflammation. On the other hand, cell-based assays suggest antiinflammatory effects of Gas-cAMP signaling. This study was designed to test whether the in vitro antiinflammatory effects of phosphodiesterase 4 inhibitors, known to increase intracellular cAMP in multiple airway cell types, attenuate the asthma-like phenotype produced by the b 2 AR agonists formoterol and salmeterol in vivo in PNMT-KO mice, based on the hypothesis that skewing b 2 AR signaling toward Gas-cAMP pathway is beneficial. Airway inflammatory cells, epithelial mucus production, and airway hyperresponsiveness were quantified. In Ova S/C PNMT-KO mice, formoterol and salmeterol restored the asthma-like phenotype comparable to Ova S/C wild-type mice. However, coadministration of either roflumilast or rolipram attenuated this formoterol-or salmeterol-driven phenotype in Ova S/C PNMT-KO. These findings suggest that amplification of b 2 AR-mediated cAMP by phosphodiesterase 4 inhibitors attenuates the asthma-like phenotype promoted by b-agonists.

show abstract

Response to salbutamol in patients with mild asthma treated with nadolol

Cited by 37 publications

References 10 publications

Advances in the Diagnosis and Management of Asthma in Older Adults

Advances in the Diagnosis and Management of Asthma in Older Adults

Radiodegradation of nadolol in the solid state and identification of its radiolysis products by UHPLC–MS method

Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β₂-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase–Knockout Mice

Contact Info

Product

Resources

About

Response to salbutamol in patients with mild asthma treated with nadolol

Cited by 37 publications

References 10 publications

Advances in the Diagnosis and Management of Asthma in Older Adults

Advances in the Diagnosis and Management of Asthma in Older Adults

Radiodegradation of nadolol in the solid state and identification of its radiolysis products by UHPLC–MS method

Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase–Knockout Mice

Contact Info

Product

Resources

About

Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β₂-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase–Knockout Mice